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1. Introduction 
Diabetic kidney disease (DKD) is the single most common cause of end stage renal  
disease (ESRD) with the annual costs of caring for patients with DKD exceeding more  
than $9 billion in the United States (Centers of Disease Control and Prevention, 2005).  
Every diabetic patient has up to a 40% lifetime risk to develop DKD, if the patient does  
not die prematurely of cardiovascular disease (CVD) (Parving, Osterby, & Ritz, 2000).  
DKD can present as different phenotypes, progressive and nonprogressive (Figure 1  
and 2). 
 
Stages of CKD GFR 
(mL/min/ 1.73m2) 
Proteinuria/Albuminuria 
and/or Hematuria 
1 ≥90 + 
2 60-89 + 
3 30-59 ± 
4 15-29 ± 
5 <15 ± 
 
Stages of DKD GFR 
(mL/min/ 1.73m2) 
Albuminuria  
(mg/g) 
1 ≥90 - 
2 60-89 30-300 
3 30-59 >300 
4 15-29 >3000 NS 
5 <15 ± 
NS= Nephrotic Range Proteinuria 
Fig. 1. A-B. The stages of CKD (A) and DKD (B). 
Approximately, a third of patients can have progressive DKD which presents with 
progressive proteinuria, mainly albuminuria, a subsequent decline in glomerular filtration 
rate (GFR), and in some patients, progression to ESRD. Clinical studies show that renal 
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vascular dysfunction can precede the onset of proteinuria in diabetes. Ishimura et al. 
demonstrated that patients with stage 1 DKD have increased resistive indices in the renal 
vasculature, indicating a diminished renal vasodilatory blood flow reserve (Ishimura et al., 
1997). Furthermore, Frauchiger et al. validated that patients with early DKD have a 
diminished renal blood flow response to nitroglycerin compared to healthy controls 
(Frauchiger, Nussbaumer, Hugentobler, & Staub, 2000). In addition, Epstein et al. elegantly 
demonstrated that renal blood flow oxygenation, as quantified by blood oxygenation level-
dependent magnet resonance imaging, is diminished in response to a water load in patients 
with stage 1 DKD compared to healthy controls, suggesting that oxygen delivery may be 
impaired in early stages of DKD, at least in part, due to vascular and/or endothelial 
dysfunction (Epstein, Veves, & Prasad, 2002). The cause for these observations is 
incompletely understood, but several studies suggest that inactivation of Nitric Oxide (NO) 
by increased reactive oxygen species (ROS) generation in diabetes may be an underlying 
mechanism. It has been suggested that increased generation of ROS in diabetes mellitus, 
namely of superoxide anion (O2-), reduces vascular endothelial function. This endothelial 
dysfunction is characterized by a decreased NO-dependent vasodilation which has been 
demonstrated in the renal vasculature of early DKD and may also contribute to the 
increased cardiovascular mortality in these patients (Dai, Diederich, Skopec, & Diederich, 
1993; Diederich, 1997; Kanwar et al., 2008). Any form of DKD is associated with a markedly 
increased cardiovascular mortality and in recent years, even low levels of albuminuria, 
which were previously thought to be normal, have been shown to be associated with up to 
10-fold increased cardiovascular mortality (Rachmani et al., 2000). 
 
  
 
   
 
Fig. 2. A-D. Different phenotypes of DKD including progressive (A-C) and non-progressive 
or slowly progressive DKD (D), GFR, glomerular filtration rate; UAE, Urine albumin 
excretion. 
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The therapeutic strategies for DKD are limited due to several factors: (1) Lack of screening 
for DKD, (2) Lack of implementation of optimal standard therapy for DKD, and (3) Current 
therapies primarily slow down, but do not halt the progression of DKD. These therapies 
include: blood pressure, lipid, glycemic, and weight control; diet and lifestyle modifications; 
antiplatelet aggregation therapy; and initiation of therapy with inhibition of the renin 
angiotensin system (RAS) by angiotensin converting enzyme inhibitors (ACEIs), angiotensin 
receptor blockers (ARBs), and renin inhibitors. 
A major role of DKD pathogenesis has been attributed to the increased generation of ROS in 
diabetes.(Figure 3) 
 
 
Fig. 3. Sources of ROS Generation in DKD 
ROS are natural by-products of oxygen metabolism that are generated during oxidative 
phosphorylation and play an important role in cell signalizing, aging, cancer prevention 
and degenerative diseases. Oxidative radicals are highly reactive ROS capable of changing 
the form and function of many cellular components. Under normal conditions, common 
ROS, including superoxide anion (O2-), hydrogen peroxide (H2O2), hydroxyl radical (OH-) 
and hypochlorous acid (HClO) are detoxified via electron transfer by cellular antioxidant 
enzyme systems (superoxide dismutase, catalase, and glutathione peroxidase). However, 
during periods of stress, including environmental, physical (e.g. radiation, ultraviolet 
light), and chemical (e.g. hyperglycemia), these free radicals are produced in excess, 
overwhelming the detoxification capacity of cellular antioxidant enzymes and causing cell 
damage. This damage is mediated directly by electron shifts or due to cytokine-mediated 
signal transduction and amplification, DNA damage and structural changes of lipids and 
proteins. 
The overproduction of ROS in the kidney has been demonstrated in both animals (Koya et 
al., 2003) and humans with DKD (Brezniceanu et al., 2007). In addition, the products of 
increased ROS generation, such as 13-hydroxyoctadecadienoic acid, dimethylarginine,  
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8-hydroxyguanosine, and oxidized glutathione are increased in DKD (Aslam, Santha, Leone, 
& Wilcox, 2006). Vascular endothelium is especially prone to ROS-mediated damage 
(Inoguchi et al., 2003; H. B. Lee, Ha, & King, 2003; H. B. Lee, Yu, Yang, Jiang, & Ha, 2003; Li 
& Shah, 2003). Superoxide anion generation has been shown to inactivate NO-dependent 
vasodilation, likely by scavenging NO and generating the very potent ROS peroxynitrite: 
NO·+ O2-  ONOO (Figure 5A) (Hogg & Griffith, 1997). 
The challenges antioxidant therapy faces in the clinic are two-fold: (1) prevention of 
further ROS generation and, (2) achieving an appropriate and constant antioxidant level 
at the site of injury (mitochondria). Many antioxidant molecules get converted to oxidant 
radicals during the redox reaction involved in scavenging ROS. Moreover, the 
mitochondria are the major site of ROS generation and it is questionable if most 
antioxidants currently in clinical use (e.g. N-acetylcysteine, vitamin C, vitamin E) are 
reaching their target and acting within the mitochondria in order to effectively decrease 
ROS generation. Some newer antioxidants, such as ubiquinones, may be more 
mitochondria-specific and will be discussed later (James, Cocheme, Smith, & Murphy, 
2005; James et al., 2007). (Figure 3 & 4) 
 
 
Fig. 4. Amelioration of ROS by Antioxidants 
Both enzymatic (NADPH oxidase, G6PDH, xanthine oxidase, NO synthase and glycolysis 
pathway enzymes) and non-enzymatic reactions (glucose auto-oxidation and advanced 
glycation) are involved in hyperglycemia-induced overproduction of ROS. Glucose-induced 
protein kinase C (PKC), advanced glycosylation end-products (AGE), polyol pathways, and 
nuclear factor kappa B (NF-kB) activation are the 4 critical pathways involved in DKD. 
Agents with potential antioxidant effects currently investigated in animals and humans 
which will be discussed below include renin angiotensin inhibitors, protein kinase  
C inhibitors, TGF-B inhibitors, pentoxifylline, selective mitochondrial antioxidants, statins, 
vitamins C and E, sodium bicarbonate, N-acetylcysteine, bardoxolone methyl, omega-3 fatty 
acids, coenzyme Q10, and tempol. 
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2. Antioxidant therapy: ROS inhibition for the treatment of DKD 
Several studies have demonstrated that inhibition of ROS generation by various therapeutic 
strategies and targeting different pathways are beneficial in the prevention and/or 
progression of DKD. An ideal antioxidant agent would be one that targets several  
ROS-generating pathways, in particular, mitochondrial-derived ROS.  Such agents studied 
for the treatment of DKD are yet to be identified. Potential novel treatment strategies may 
include the following (see also Figure 5). 
 
 
(A) 
 
(B) 
Fig. 5. A-B. Mitochondrial pathways of ROS generation in non-diabetic (A) and diabetic 
conditions (B). 
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2.1 Glycemic control 
In hyperglycemia, excess glucose undergoes auto-oxidation and glycolysis to produce large 
amounts of NADH and FADH2 which feed into and overwhelm the electron transport 
chain, causing electron leaks and ROS overproduction in renal and other cells (El-Osta et al., 
2008). Currently, standard therapy for DKD includes tight glycemic control, directed by 
glycosylated hemoglobin A1c (HbA1c) levels to prevent hyperglycemia-induced, ROS-
related DKD. Target HbA1c levels of less than 7.0% have been recommended to improve 
DKD and/or prevent its progression in several trials (National Kidney Foundation, 2010). 
Generally, elevated HbA1c levels are indicative of chronic hyperglycemia, but insensitive to 
detect transient hyperglycemic episodes. However, events of transient hyperglycemia  
(as short as 6 hours of hyperglycemia) have been shown to induce long-lasting activation of  
NF-kB (El-Osta et al., 2008) and are now considered a risk factor for diabetic complications 
independent of HbA1c levels. 
2.2 Inhibition or blockade of Renin-Angiotensin System (RAS) 
Angiotensin II is a major constituent of the RAS and has been shown to be an important 
pathogenetic factor in DKD development (Andersen, Tarnow, Rossing, Hansen, & Parving, 
2000). Inhibition of the RAS by ACEIs, ARBs, and renin inhibitors have been shown to delay 
the onset and/or progression of DKD in numerous studies. A meta-analysis by Kunz et al 
analyzed 110 trials and found that ACEI and ARBs significantly decreased proteinuria, one 
of the early signs of DKD, in renal disease. No conclusions could be made, however, 
regarding preservation of kidney function from this analysis due to the variable quality of 
these studies and their short duration (Kunz et al 2008). Another meta-analysis of 24 studies 
found that RAS blockers reduce the risks of ESRD and doubling of serum creatinine in 
diabetic nephropathy patients, but do not affect all-cause mortality (Sarafidis et al 2008). The 
beneficial effects of RAS inhibitors in DKD may in part be due to their antioxidant 
properties (Onozato, Tojo, Goto, Fujita, & Wilcox, 2002). However, the use and benefit of 
these agents is limited by potentially harmful side effects such as hyperkalemia, reduction in 
the GFR, and failure to completely halt disease progression.  
2.3 Inhibition of protein kinase C (PKC) 
Hyperglycemia-mediated overexpression of protein kinase C (PKC)-ǃ results in activation of 
NADPH oxidase, a lysosomal enzyme involved in ROS generation which is also increased in 
experimental models of DKD (Onozato et al., 2002). Ruboxistaurin, a PKC-ǃ inhibitor, 
reduced proteinuria in animal models (Inoguchi et al., 2003) and humans (Tuttle et al., 2005). 
However, larger clinical trials are pending to confirm the safety and validate the prospective 
benefits of ruboxistaurin. Other PKC-ǃ inhibitors are currently under investigation for 
possible use in the treatment of DKD. 
2.4 Inhibitors of transforming growth factor-β (TGF-β) 
Transforming growth factor-ǃ is a family of growth and differentiation factors that includes 
TGF-ǃ1, ǃ-2, and ǃ-3 , activins, and bone morphogenic proteins (Bottinger, 2007). TGF-ǃ1 is 
a pleotrophic cytokine with complex biological activities that depend on cell type and cell 
context. Cell cycle control, regulation of early development, cell differentiation, 
angiogenesis, and immune system regulation are all activities ascribed to TGF-ǃ1 (Schmidt-
Weber & Blaser, 2004{Ghosh, 2005 #132). TGF-ǃ is also a major regulator of the extracellular 
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matrix and tissue repair. A highly validated deleterious action of TGF-ǃ is its contribution to 
the progressive fibrosis of CKD (Bottinger & Bitzer, 2002) and DKD (Chen et al., 2001).  
TGF-ǃ1 appears to be the predominant isotype mediating disease progression. Experimental 
evidence indcates that TGF-ǃ1 is the most abundant isoform expressed in the kidney. The 
TGF-ǃ2 and-ǃ3 isoforms have been shown to mediate part of their effect through 
upregulation of ǃ1 expression (Chen et al., 2001). In addition, it has been demonstrated in 
the db/db mouse model of DKD that a neutralizing monoclonical antibody (mAb) specific for 
TGF-ǃ-1 was as effective in reducing renal damage as an mAb against all 3 TGF-ǃ isoforms 
(Ziyadeh et al., 2000). Thus, modulation of TGF-ǃ1 activity would be expected to retard 
DKD progression without interfering with either important regulatory roles of TGF-ǃ2 and 
–ǃ3. Humanized IgG4 mAb that has potent and selective neralizing activity against active 
TGF-ǃ1 (known as CAT-192) is being tested for DKD therapy. Monoclonal antibodies 
against TGF-ǃ are currently under clinical investigation for DKD. 
TGF-ǃ is not only fibrogenic and causes glomerulosclerosis(Sharma, Jin, Guo, & Ziyadeh, 
1996) but can also generate ROS by inducting NADPH oxidase (Misra & Rabideau, 2000). 
Pirfenidone is an inhibitor of fibroblast growth factor, platelet derived growth factor, and 
TGF-ǃ. Pirfenidone has antioxidant properities, and has been shown to slow the progression 
of glomerulosclerosis (Misra & Rabideau, 2000; RamachandraRao et al., 2009). Pirfenidone 
has been clinically used for the treatement of interstitial lung disease, and recently been 
shown to have beneficial effects for DKD (Sharma et al., 2011).  
2.5 Inhibition of non-enzymatic glycation 
Advance glycation end-product (AGE) are endogenous proteins which are non-
enzymatically glycated following auto-oxidation of glucose, primarily in diabetes. The 
interaction between AGE and their receptors (RAGE) in the kidney has been shown to 
activate expression of NF-kB which stimulates ROS production, contributing to DKD 
(Schmidt et al., 1995). Pyridoxamine inhibits glycation of proteins and decreases AGE 
deposition in animal models of DKD (Degenhardt et al., 2002). One clinical trial in DKD 
patients who were treated with pyridoxamine demonstrated a reduced progression of DKD 
defined as the improvement of the serum creatinine; however, a reduction of urinary 
albumin excretion was not observed (Williams et al., 2007). A multi-center, randomized 
controlled trial studying the effects of pyridoxamine in DKD is currently being conducted. 
2.6 Removal of catalytic iron 
Hyperglycemia-induced glycation of proteins increases their affinity for iron, forming 
glycochelates. Glycochelates, as well as catalytic iron, have also been implicated in DKD 
(Swaminathan, Fonseca, Alam, & Shah, 2007). Desferoxamine, a commonly used iron 
chelator(Miller, M.J., 1989), restores endothelial function mediated by inhibition of ROS 
(Koo, Casper, Otto, Gira, & Swerlick, 2003). The drug has the ability to penetrate cell 
membranes and chelate intracellular iron species. The role of iron chelators in decreasing 
ROS in DKD warrants evaluation in randomized controlled clinical trials. 
2.7 Role of pentoxifylline 
Pentoxifylline has numerous pharmacological roles, including antioxidant and platelet 
aggregation inhibitor. For example, tissue necrosis factor ǂ (TNF-ǂ) promotes the local 
generation of ROS in the glomerular capillary wall, increasing albuminuria in DKD 
(McCarthy et al., 1998). Pentoxifylline decreases TNF-ǂ expression and reduces proteinuria 
www.intechopen.com
 
Diseases of Renal Parenchyma 
 
210 
in DKD (Navarro et al., 1999). Clinical trials have demonstrated that pentoxifylline has 
additional mild benefits in reducing albuminuria in DKD patients who are already on ACEI 
or ARB therapy (Harmankaya, Seber, & Yilmaz, 2003; Navarro, Mora, Muros, & Garcia, 
2005). However, pentoxifylline has anti-platelet aggregating properties and as such, may 
increase the risk for bleeding in patients who are already on aspirin therapy (unpublished 
observations by the authors). 
2.8 Selective mitochondrial antioxidants 
Some of the newer developed antioxidants are the ubiquinones, and in particular, MitoQ10 
has been characterized as an effective mitochondrial antioxidant (Green, Brand, & Murphy, 
2004). Furthermore, MitoQ10 is not itself converted to a ROS after it scavenges ROS, making 
it a safer antioxidant (James et al., 2005; James et al., 2007). Thus, MitoQ10 might be a 
promising new agent for the treatment of DKD. Idebenone (Hausse et al., 2002), is another 
safe mitochondrial antioxidant which has a high mitochondrial uptake. Neither the role of 
Idebenone nor MitoQ10 have been studied yet in the treatment of DKD and remain to be 
elucidated. 
2.9 Statins 
Statins have been shown to have multiple antioxidant properties and improve vascular 
remodeling (Briones et al., 2009). Statins have also been shown to reduce proteinuria 
(Nakamura et al., 2005) and the progression of DKD (Agarwal, 2007). Therefore, patients 
with DKD may benefit from intensified statin therapy, even in the setting of an already 
controlled LDL cholesterol level. In our practice, we have observed a significant reduction in 
urinary albumin excretion in patients with progressive DKD who are taking statins and are 
either intolerable for ACEI/ARB therapy or who are already on maximal ACEI/ARB 
therapy (unpublished findings). Whether these benefits for the treatment of DKD are due to 
the antioxidant properties of statins, still needs to be determined. Furthermore, the recently 
published results of the Study of Heart and Renal Protection (SHARP trial) demonstrated 
the safety of statins in patients with DKD, however, no significant benefits with regard to 
improved kidney function have been demonstrated ( Baigent, C. et al. 2011). However, a 
population based cohort study demonstrated possible renal toxic effects of statin therapy, in 
that all statins were associated with acute renal failure over five years, however, the risk of 
that was extremely low (Hippisley-Cox and Coupland, 2010). For example, in women, the 
number needed to harm (NNH) for an additional case of acute kidney injury over years was 
434 (ranging from 284-783). 
2.10 Vitamin C and E 
Vitamin C activates vitamin E and each exhibits multiple antioxidant effects, including 
inhibition of monocyte adhesion. Their effects have been shown in animal models of 
experimental diabetes mellitus (E. Y. Lee, Lee, Hong, Chung, & Hong, 2007; Nakano et al., 
2008; Simsek, Naziroglu, & Erdinc, 2005). Furthermore, vitamin E protected against ROS-
induced DKD in diabetic mice with the haptoglobin (Hp) 2-2 genotype (Nakhoul et al., 
2009). A small randomized clinical trial of 69, type 2, diabetic patients with DKD, 
demonstrated a benefit with the administration of vitamin C (200 mg) and E (100 IU) in 
reducing urinary albumin excretion (Farvid, Jalali, Siassi, & Hosseini, 2005). Larger trials are 
warranted to further validate these findings. 
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2.11 Sodium bicarbonate 
The administration of sodium bicarbonate for patients with DKD has primarily been utilized 
for the prevention of contrast-induced acute kidney injury (CIAKI) (Brar et al., 2008; Maioli 
et al., 2008; Merten et al., 2004). The pathogenesis of CIAKI involves renal ischemia and ROS 
generation. Therefore, the use of sodium bicarbonate, a pro-oxidant, to countervail an ROS 
mediated and generated process such as CIAKI, would seem questionable and counter-
intuitive. Consistent with these biochemical observations (From et al., 2008), a retrospective 
cohort study of 7,977 patients undergoing contrast media (CM) procedures found that the 
administration of sodium bicarbonate for CIAKI prevention was associated with a 3-fold 
higher risk to develop CIAKI, compared to N-acetylcysteine alone. However, a recent study 
found a decrease in the progression of chronic kidney disease (CKD) and DKD in patients 
taking sodium bicarbonate for 2 years (de Brito-Ashurst, Varagunam, Raftery, & Yaqoob, 
2009). However, sodium bicarbonate did not change proteinuria in these patients. Further 
studies are needed to validate these findings and the underlying mechanism. 
2.12 N-acetylcysteine (NAC) 
NAC has several antioxidant properties, including induction of synthesis of glutathione, 
which is used by glutathione peroxidase to reduce H2O2. Furthermore, NAC has been 
successfully utilized for the prevention of CIAKI in patients with DKD, since both DKD  
and CIAKI are associated with increased ROS generation (A. Pflueger, Abramowitz, & 
Calvin, 2009). 
The first study of NAC for CIAKI prevention was conducted by Tepel and colleagues (Tepel 
et al., 2000). The investigators used 600 mg orally, twice daily, on the day before and the day 
of iodine CM administration and 0.45% saline intravenous hydration in comparison to 
0.45% saline hydration alone. Forty-eight hours after CM administration, CIAKI tended to 
occur and the serum creatinine tended to increase from 2.4 to 2.6 mg/dL (P=0.18) in the 
control group, whereas in the NAC group, serum creatinine decreased significantly from 2.5 
to 2.1 mg/dL (P=0.01). Several studies followed with conflicting results (Fishbane, 2008; 
Sterling, Tehrani, & Rudnick, 2008). Several factors have been postulated to contribute to 
these varying results, including different formulations of NAC. 
Dose and treatment duration are the most decisive factors in NAC’s prevention of CIAKI. 
NAC is commonly given for only two days (Tepel et al., 2000), and treatment duration may 
be too brief to effectively countervail CIAKI-induced ROS production. This treatment 
duration was chosen because ROS production was thought to occur only shortly after CM 
induction. However, this concept may need to be revised since the effects of ROS-induction 
may last much longer than previously assumed, particularly in diabetes. Recently, Michael 
Brownlee and his group (El-Osta et al., 2008) demonstrated that short-term exposure (1 
hour) of high glucose induces ROS-mediated, long-lasting activation of NF-kB subunit p65 
in aortic endothelial cells, both in vitro and in vivo. Interestingly, the effects of this short-
term ROS-mediated induction on transcription factor activation could be observed for at 
least six days after the initial induction. Therefore, CIAKI prevention strategies may need to 
be applied for longer than two days in order to countervail ROS production and induction 
of other cell signaling mechanisms. In our practice, we have given NAC as long as six days 
after CM administration with good tolerability and outcome (unpublished observation). 
Furthermore, like many antioxidants, NAC has a very short plasma half-life and plasma 
target levels are difficult to assess. Dosing twice daily may be insufficient to achieve 
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consistent renoprotective effects. Moreover, the bioavailability of NAC by oral 
administration is limited by extensive first-pass metabolism, perhaps explaining why 
studies of intravenous NAC have tended to show greater efficacy in CIAKI prevention 
(Fishbane, 2008; Sterling et al., 2008). 
NAC has been successfully used for the treatment of acetaminophen-induced ROS liver 
toxicity, typically utilizing 40-fold higher doses than the current recommended dose of NAC 
(MW: 163.19) for CIAKI prevention, which is 1200 mg daily or 7 x 10-3 moles. The daily 
physiological production of superoxide anion (MW: 31.99) has been estimated to be 1.75 kg, 
or 5.5 x 104 moles (Frei, 1994). Furthermore, ROS production is increased in patients with 
diabetes and CIAKI. Therefore, it may be presumptuous to assume that 7 x 10-3 moles NAC 
would cause a meaningful reduction in a daily ROS generation of more than 5.5 x 104 moles 
of superoxide anion, which is a greater than 7 million-fold difference. Marenzi et al. have 
demonstrated that doubling the dose of NAC (1200 mg twice daily) improves CIAKI 
prevention rates (Marenzi et al., 2006). Thus, it would seem that higher doses of NAC and 
longer treatment periods are necessary for more efficacious CIAKI prevention. No clinical 
trials studying the long-term effects of NAC on DKD have been conducted, though given its 
low cost and good side-effect profile, they may well be worthwhile. 
2.13 Induction of transcription factor Nrf2: Bardoxolone methyl 
Bardoxolyne methyl, an inducer of transcription factor Nrf2, can induce the generation of 
over 250 antioxidant enzymes (Dinkova-Kostova et al., 2005). Recently, Bardoxolone methyl 
has been shown to significantly improve the creatinine GFR and cystatin C GFR in patients 
with DKD after only 4 weeks (Schwartz, Denham, Hurwitz, Meyer, & Pergola, 2009). 
However, Bardoxolone methyl did not improve urinary albumin excretion. Moreover, a 
recent landmark phase 2 trial of 227 adults with CKD and type 2 DM demonstrated that 
bardoxolone methyl improved GFR by at least 8.2 +/-1.5 ml/min over placebo after 24 
weeks of treatment and that this effect was maintained after a year of therapy. (Pergola, et 
al., 2011). Even though bardoxolone did not effect proteinuria in this trial.  
2.14 Role of haptoglobin (Hp) genotype 
Hp is a hemoglobin-binding protein that has a major role in protecting against heme-
induced ROS (Levy et al., 2010; Nakhoul, Miller-Lotan, Awaad, Asleh, & Levy, 2007). There 
are three common Hp genotypes: Hp 1-1, Hp 2-1, and Hp 2-2. The antioxidant protection 
provided by Hp in DKD has been shown to be genotype-dependent in animals (Miller-
Lotan et al., 2005) and humans (Burbea et al., 2004), with Hp 1-1 providing superior 
antioxidant protection compared with Hp 2-2. Diabetic patients with the genotype Hp 2-2 
are more likely to develop DKD than those with the Hp 2-1 or Hp 1-1 genotypes (Burbea et 
al., 2004; Levy et al., 2010; Nakhoul et al., 2007). However, no clinical therapeutic application 
has been studied in connection with Hp for DKD. 
2.15 Plant-derived omega-3 fatty acids: Alpha linolenic acid 
Omega-3 fatty acids are incorporated into cell membrane lipids, making them less 
susceptible to a free radical attack. Additionally, omega-3 fatty acids up-regulate the  
gene expression of antioxidant enzymes and down-regulate the gene expression of genes 
associated with ROS production (Takahashi et al., 2002). One of the most important plant-
derived omega-3 fatty acids is alpha linolenic acid, found in rapeseed (canola),  
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chia, kiwifruit seed, soybean oil and in especially high content in flaxseed oil (Kris-
Etherton, Harris, & Appel, 2003). Alpha linolenic acid has been shown to prevent the 
progression of DKD including reduction of proteinuria, glomerular sclerosis, and tubular 
abnormalities in streptozotocin (STZ)-induced diabetic rats (Barcelli, Weiss, Beach, Motz, 
& Thompson, 1990). 
2.16 Animal-derived omega-3 fatty acids: Fish oil 
Important animal-derived fatty acids include eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) found primarily in fish oil. Among their many antioxidant 
effects, EPA has been shown to inhibit the production of phospholipase A2, an important 
pro-oxidant enzyme (von Schacky, Siess, Fischer, & Weber, 1985; Zhang et al., 2006), and 
DHA has been shown to decrease NADPH oxidase activity (Diep et al., 2002). However, 
these fatty acids are also susceptible to auto-oxidation and may, theoretically, increase ROS 
and lead to progression of DKD (Nenseter & Drevon, 1996). 
The antioxidant effects of fish oil-derived omega-3 fatty acids have also shown promising 
results in animal models of DKD. Several studies have noted a decrease in albuminuria 
(Garman, Mulroney, Manigrasso, Flynn, & Maric, 2009; Hagiwara et al., 2006; Zhang et al., 
2006) and general proteinuria (Velasquez et al., 2003) in rat and mouse models of diabetes 
mellitus. The percentage of glomerular abnormalities, defined as either mesangial expansion 
(Velasquez et al., 2003; Zhang et al., 2006) or glomerulosclerosis (Garman et al., 2009), was 
less in rodent diabetic models fed omega-3 fatty acids, versus placebo. The extent of 
tubulointerstitial fibrosis was also less in these animals (Garman et al., 2009; Velasquez et al., 
2003; Zhang et al., 2006). 
Fish oil-derived omega-3 fatty acid effects on human DKD subjects have been less 
impressive. Two double-blind, randomized controlled studies, each involving 29 type 1 
diabetic patients at a tertiary center, were performed comparing fish oil (4.6 g fish oil/d) 
with olive oil placebo (Myrup et al., 2001; Rossing et al., 1996). In one of these studies, 
although triglyceride and VLDL levels were lower in the fish oil group, total and LDL 
cholesterol were increased in that group, when compared to placebo (Rossing et al., 1996). 
There was no significant change in albuminuria,(Myrup et al., 2001; Rossing et al., 1996) nor 
in GFR (Rossing et al., 1996) between the fish oil and control groups in type 1 diabetic 
patients. Currently, the data in vivo concerning the antioxidant effect of omega-3 fatty acids 
is inconclusive. 
2.17 Red wine polyphenols 
The antioxidant renoprotective effects of red wine have largely been attributed to their 
polyphenol constituents, which include resveratrol, quercetin, anthocyanins, gallic acid, 
catechin, tannic acid and myercetin. Many other alcoholic beverages as well as tea, garlic, 
and other plants also are known to contain increased amounts of polyphenols (Rodrigo & 
Bosco, 2006). Among their antioxidant mechanisms, polyphenols have been shown to 
increase the activity of glutathione peroxidase and prevent deactivation of endothelial nitric 
oxide synthase (eNOS). eNOS is an isoenzyme of nitric oxide synthase (NOS) which uses 
NADPH to generate NO during oxidation of L-arginine and leads to vasodilation. Low 
starting reagent levels result in uncoupling of NOS and generation of superoxide via 
NADPH oxidase instead. Decreased NO-dependent renal vasodilation has been 
demonstrated in early DKD in both animals (Matsumoto, Koshiishi, Inoguchi, Nawata, & 
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Utsumi, 2003; A. C. Pflueger, Larson, Hagl, & Knox, 1999; A. C. Pflueger, Osswald, & Knox, 
1999; A. C. Pflueger, Schenk, & Osswald, 1995) and humans (Frauchiger et al., 2000), also 
suggesting an uncoupling of the NO signal transduction pathway. 
Several studies have also been carried out on rodent DKD models. For example, direct 
quercetin administration resulted in reduced levels of oxidative stress and attenuation of 
diabetic proteinuria, polyuria, serum creatinine, and blood urea nitrogen in STZ-induced 
diabetic rats when compared to STZ diabetic controls (Anjaneyulu & Chopra, 2004). Green 
tea polyphenol with partially hydrolyzed gaur gum has also been shown to reduce 
oxidative stress and improve kidney weight, blood urea nitrogen levels, serum creatinine, 
and creatinine clearance in partially nephrectasized and STZ-induced diabetic rats 
(Yokozawa, Nakagawa, Oya, Okubo, & Juneja, 2005). Another study on STZ rats led by the 
Montilla group included administration of red wine four weeks after, as well as two weeks 
prior to STZ injection. Treatment with red wine significantly prevented changes induced by 
STZ, including decreased albuminuria, proteinuria, glucosuria, triglycerides, and total 
cholesterol, when compared with the control STZ rat group (Montilla et al., 2005). 
Several studies in humans suggest that chronic exposure to moderate amounts of red wine 
improve DKD. A large cross sectional study involving 157 type 1 diabetes patients with 
macroalbuminuria found that those who consume moderate amounts (30-70 g/week) of 
alcoholic beverages including red wine and beer, had a significantly lower incidence of 
macroalbuminuria than those who did not (Beulens et al., 2008). A randomized, controlled 
study involving moderate red wine versus white wine consumption (4 oz/day, for 6 
months) in type 2 diabetes patients with DKD showed a statistically significant decrease in 
proteinuria, as well as in excretion of 8-hydroxydeoxyguanosine and liver type fatty acid-
binding protein (markers of tubulointerstitial damage and of CKD, respectively) only in the 
red wine group (Nakamura, Fujiwara, Sugaya, Ueda, & Koide, 2009). Red wine has a higher 
content of polyphenols than white wine. Another randomized, controlled trial in diabetic 
patients showed that the administration of moderate amounts of red wine with a 
polyphenol-enriched, low-iron-available, carbohydrate-restricted diet was 40-50% more 
effective in improving renal and overall survival rates than the standard protein restriction 
diet (Facchini & Saylor, 2003). Further studies need to be conducted in order to investigate 
the full benefit of these compounds in patients with DKD. 
2.18 Berry polyphenols 
An important subgroup of polyphenol-containing foods are berries, such as acai berries, 
bilberries, raspberries, black currants, strawberries, blueberries, lingonberry extracts, and 
grapes (Pacheco-Palencia, Talcott, Safe, & Mertens-Talcott, 2008; Schauss et al., 2006; Seeram 
et al., 2008; Spada, de Souza, Bortolini, Henriques, & Salvador, 2008; Sun et al., 2010). 
The most beneficial antioxidant molecules in berries are polyphenolic acids, including gallic 
acid, hydroxybenzoic acids, and flavanoids, including flavan-3-ols along with cyaniding 3-
O- rutinoside and cyaniding 3-O-glucoside. One example is the acai fruit berry. Acai is a 
palm fruit from South America, and the pulp and oil extracts have been studied and shown 
to inhibit cell proliferation and demonstrate antioxidant properties (Mertens-Talcott et al., 
2008; Pacheco-Palencia et al., 2008). Acai extract has been shown to improve endothelium-
dependent vasodilatation in the mesenteric vascular bed of rats (Rocha et al., 2007). 
Furthermore, acai juice and pulp have been shown to increase plasma antioxidant capacity 
in humans up to threefold, albeit without an elevation in urinary antioxidants (Mertens-
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Talcott et al., 2008). The benefits of the acai berry from pulp and oil in vitro have been 
demonstrated in humans with a dual effect on ROS generation, in that lower concentrations 
of acai extract may increase ROS generation, whereas higher concentrations have 
antioxidant properties (Pacheco-Palencia et al., 2008). 
The antioxidant capacity of polyphenolics has further been demonstrated in freeze-dried 
acai extract (Schauss et al., 2006) and in other frozen fruits (Spada et al., 2008), suggesting 
that processed food items still retain antioxidant properties (Mertens-Talcott et al., 2008). 
In one study, the antioxidant property of acai extract, assessed by SOD-induced scavenging 
of superoxide anion, was remarkably higher than in other reported fruit and vegetables. 
Seeram and colleagues also compared the antioxidant properties of several polyphenol-rich 
beverages, including acai juice. Their analyses revealed that the highest antioxidant index 
and gallic acid equivalence occur in the following order, from highest to lowest antioxidant 
properties: pomegranate juice, red wine, grape juice, blueberry juice, blackberry juice, acai 
juice, cranberry juice, orange juice, apple juice, green tea, and black tea (Seeram et al., 2008). 
2.19 Role of heme oxygenase (HO) 
HO is a heme degradation enzyme which is expressed in several organs, including liver and 
kidney. It is involved in the production of several molecules known to have antioxidant 
properties including, carbon monoxide, biliverdin/bilirubin, and iron/ferritin (Stocker, 
Yamamoto, McDonagh, Glazer, & Ames, 1987). HO-2 is constituitively expressed, while the 
inducible isoform, HO-1 is generated in response to oxidative stress. HO’s specific functions 
in the kidney include maintaining renal blood flow, vasotonic equilibrium, and sodium and 
fluid absorption in the Loop of Henle (Abraham, Cao, Sacerdoti, Li, & Drummond, 2009). 
HO-1 has also been shown to enhance renal mitochondrial transport carriers and 
cytochrome c oxidase activity (Di Noia et al., 2006). CO, one of the products of heme 
degradation, has been shown to have both pro-oxidant (via vasoconstriction) and 
antioxidant (via vasodilation) effects (Abraham et al., 2009; Lamon et al., 2009). 
The antioxidant effects of HO-1 have also been demonstrated in rodent DKD models. 
Goodman, et al. examined the differences between HO-2 (-/-) knockout and HO-2 (+/+) 
wildtype mice. When diabetes was induced by STZ in both groups, HO-2 (-/-) mice 
demonstrated increased plasma creatinine levels, acute tubular damage and microvascular 
pathology when compared to their wildype HO-2 counterparts. An inverse relationship was 
demonstrated between HO and superoxide levels. These results clearly indicate that HO 
activity is essential in preserving renal function and morphology in STZ-induced diabetic 
mice (Abraham et al., 2009; Goodman et al., 2006). 
Although there are studies showing the causative role of pro-oxidants, including 
endothelin-1, TGF-ǃ and platelet-derived growth factor (PDGF) in DKD patients (Gilbert, 
Akdeniz, Allen, & Jerums, 2001; Jandeleit-Dahm, Allen, Youssef, Gilbert, & Cooper, 2000; 
Langham et al., 2003) and HO-1 has been shown to inhibit these pro-oxidants (Abraham et 
al., 2009; A. Pflueger et al., 2005), no human studies have been performed demonstrating the 
direct effect of HO on alleviating DKD. 
2.20 Role of bilirubin 
As noted above, bilirubin is a degradation product of HO and is long known to have 
antioxidant properties (Stocker, Glazer, & Ames, 1987; Stocker, Yamamoto, et al., 1987). The 
ROS scavenging properties of bilirubin have been demonstrated in rat tissue samples. In rat 
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liver tissue exposed to oxidative stresses including UVA radiation, menadione bisulfite, or 
copper sulfate, the addition of low doses of bilirubin prevented lipid peroxidation and 
attenuation of glutathione reductase antioxidant enzyme (Ossola, Groppa, & Tomaro, 1997; 
Ossola, Kristoff, & Tomaro, 2000; Ossola & Tomaro, 1995, 1998). Bilirubin and biliverdin 
(bilirubin’s immediate precursor) inhibit CO-induced superoxide generation in rat renal 
arteries (Lamon et al., 2009). Bilirubin also demonstrated important effects on angiotensin II 
(AII) activity: in vitro, AII administration results in vascular smooth muscle contraction and 
generation of superoxide anion, a powerful ROS. Administration of bilirubin was shown to 
normalize the pressor and pro-oxidant effects of AII (A. Pflueger et al., 2005). 
Despite the aforementioned beneficial properties, high levels of bilirubin have also been 
associated with adverse effects in cells. In our own experiments, higher bilirubin 
concentrations (≥100 μM, ≥5.8 mg/dL) were associated with apoptosis (unpublished 
observations by the authors). Bilirubin has also been shown to inhibit mitochondrial 
enzymes, cause DNA damage, and inhibit protein synthesis (Chuniaud et al., 1996). 
Moreover, bilirubin has been shown to have inhibitory effects on ion exchange and water 
transport in the kidney (Sellinger, Haag, Burckhardt, Gerok, & Knauf, 1990). 
A few studies involving bilirubin and renal damage that may mimic DKD have been carried 
out in animal models. Recently, Adin and colleagues demonstrated that micromolar doses of 
bilirubin improved renal vascular resistance, urine output, GFR, tubular function, and 
mitochondrial integrity in rats exposed to ischemia/reperfusion renal injury (which can occur 
in DKD) (Abraham et al., 2009; Adin, Croker, & Agarwal, 2005). The attenuating effect of 
bilirubin on AII has also been shown in animal models although AII administration caused a 
significant decrease in GFR and impairment of both endothelium-dependent and 
endothelium-independent vasodilators in control rats, hyperbilirubinemic Gunn rats were 
resistant to such effects (A. Pflueger et al., 2005). Another study by Fujii et al. suggests a 
protective effect of bilirubin in diabetic animal models via downregulation of NADPH 
oxidase. Diabetic, hyperbilirubinemic Gunn j/j rats and biliverdin-treated diabetic db/db mice 
were found to have a lack of progression of mesangial expansion and less albuminuria than 
the control diabetic, j/+ Gunn rats and non-biliverdin-treated db/db mice, respectively, 
suggesting a bilirubin- and biliverdin-induced resistance to the development of DKD. In 
vascular endothelial and mesangial cells cultured from these animals, bilirubin and biliverdin 
were found to significantly inhibit NADPH-dependent superoxide production, as well as 
hyperglycemic- and AII-induced production of ROS, suggesting that this bilirubin- and 
biliverdin-induced protection is mediated by an antioxidant mechanism (Fujii et al., 2010). 
Several human studies have recently been conducted studying the antioxidant effects of 
bilirubin on DKD. A cross-sectional, population-based study of 93,909 Korean subjects found 
that CKD due to diabetes mellitus was significantly lower in women with higher bilirubin 
levels, but not in men (Han et al., 2010). However, another cross-sectional study using 
demographic data from 13,184 US patients found higher serum bilirubin levels to be 
associated with lower estimated GFR and higher albuminuria, but found no significant 
associations in diabetic patients (Targher et al., 2009). A recent case control study compared 
bilirubin levels of 32 type 2 diabetic patients with DKD to those of 32 likewise diabetic patients 
without DKD, matched for gender, age, and diabetes duration. Bilirubin was 5.5 +/-2.3 umol/l 
in cases versus 7.3+/- 3.3 umol/l in controls (P = 0.02), suggesting a protective effect of 
bilirubin on DKD in humans (Zelle, Deetman, Alkhalaf, Navis, & Bakker, 2011). 
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2.21 Role of coenzyme Q10 
Coenzyme Q10 (also known as ubiquinone, or “Q10”) is a lipid-soluble component of the 
electron transport chain. In its reduced form (ubiquinol-10), coenzyme Q10 acts as an 
antioxidant, inhibiting lipid peroxidation and free radical oxidative damage.  
Studies involving Q10’s renal effects have thus far been sparse. No rodent studies focusing 
on DKD have been performed. However, the effects of Q10 on renal function in human 
diabetics are beginning to be conducted. A 1998 study by Suzuki (Suzuki et al., 1998) and 
colleagues studied the effect of Q10 on 28 subjects with a rare form of diabetes called 
maternally inherited diabetes mellitus and deafness (MIDD), caused by a mutation of one of 
the tRNA genes in the mitochondrial DNA. The subjects were given daily doses of 150mg of 
Q10 over a period of three years. Results showed that Q10 improved insulin secretory 
response, post-exercise lactate levels, and progression of hearing loss in these patients. 
However, Q10 was not shown to improve diabetic complications in these patients, including 
DKD. 
A recent randomized, controlled 8-week trial involving 74 subjects by Mori and colleagues 
showed that when taken in conjunction with omega-3 fatty acids (4g/d), Q10 (200mg/d) 
improves systolic and especially diastolic blood pressure in (non-diabetic) moderate-to-
severe CKD patients. This effect on diastolic blood pressure using combination therapy was 
only marginally better than the results of omega-3 fatty acids being used alone (3.4 mm Hg 
decrease for combination therapy versus 2.9 mm Hg decrease for omega-3 alone), and thus, 
the effects of Q10 alone on blood pressure need confirmation. When Q10 was used alone on 
such patients, no benefit on blood pressure was observed; in fact, Q10 demonstrated a slight 
tachycardic effect.  Since hypertension is an important prognostic factor in the progression 
of CKD, the authors of this study suggested that Q10 may slow down CKD progression 
when used in conjunction with omega-3 fatty acids (Mori et al., 2009). However, more 
studies involving Q10 used alone and in combination with omega-3 fatty acids would have 
to be performed in order to elucidate its effect on CKD.  Studies involving Coenzyme Q10 
and diabetes-induced CKD and other manifestations of DKD would also need to be 
performed in order to investigate Q10’s effect on this aspect of diabetes. 
2.22 Tempol 
Nitroxides, also known as superoxide dismutase mimetics, are a class of potent, synthetic 
antioxidants. One of the nitroxides, tempol, has been studied extensively for its antioxidant 
properties. Tempol metabolizes superoxide anion to by a catalase-like action. Furthermore, 
nitroxides metabolize, detoxify, or prevent the formation or action of a wide range of other 
ROS (Wilcox & Pearlman, 2008). 
In animals, tempol has been shown to prevent the development of hypertension, 
proteinuria, oxidative ROS, podocyte damage, and upregulation of the aldosterone 
effector kinase-1 in glomerular podocytes of uni-nephrectomized rats (Ebenezer, 
Mariappan, Elks, Haque, & Francis, 2009). The authors have suggested that the beneficial 
effects of tempol on the reduction of proteinuria and glomerular damage are due to its 
antioxidant properties (Wilcox & Pearlman, 2008). Interestingly, tempol has been shown 
to improve renal oxygenation in rats and thereby may improve bioavailability of NO. 
Numerous studies have demonstrated blood pressure-reducing effects of tempol which 
are outlined in a detailed review article published by Wilcox and Pearlman (Wilcox & 
Pearlman, 2008). Tempol has also been demonstrated to reduce SOD activity in the renal 
cortical tissue of diabetic Zucker rats, thereby reducing the expression of numerous pro-
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oxidant factors such as TNF, NF-kB and NADPH oxidase (Ebenezer et al., 2009). 
Furthermore, the reduction of renal SOD reduced the progression of DKD in the C57 BL\6 
Akita diabetic mouse model (Fujita et al., 2009). 
However, to date, tempol has never been studied in clinical trials for the treatment of DKD. 
Although tempol has potential properties to be effective in clinical trials, it can act as a pro-
oxidant when used in high doses. Therefore, appropriate dosing regimens have to be 
determined clinically (Wilcox & Pearlman, 2008). 
2.23 Other potential antioxidants for the treatment of DKD 
Other potential antioxidant agents for the treatment of DKD include the following, with the 
potential antioxidant mechanism in parenthesis: selenium (cofactor for glutathione 
peroxidase), reduced glutathione (reducing agent by virtue of an SH-group), ceruloplasmin 
(binding iron), transferrin (binding iron), albumin (binding iron and copper), uric acid 
(binding iron and copper), amino-steroids (e.g. methylprednisolone; inhibit lipid 
peroxidation by non-glucocorticoid action), metformin (inhibits lipid peroxidation, increases 
SOD and glutathione levels), thiazolidinediones (inhibit lipid peroxidation, decrease 
inflammatory mediators, decrease p47phox expression), folate (decreases eNOS and xanthine 
oxidase-mediated O2- production), estrogen (decreases eNOS transcription), NOS inhibitors 
(decrease NO and potentially ONOO-), endothelin receptor antagonists, and vitamin B. 
However, these agents have not been studied systematically to determine their clinical 
effects in the treatment of DKD and warrant further evaluation. 
3. Conclusions 
The increased generation of ROS production in diabetes plays a critical role in the 
pathogenesis of DKD. Appropriate and successful antioxidant therapy for the treatment of 
DKD will vitally depend on several factors, including: mechanism of action, site of action, 
auto-oxidation and conversion to ROS while serving as an antioxidant, plasma half-life, 
mode of delivery, safety, and tolerability. In the past, the benefits of antioxidant therapy 
have been limited by ineffective targeting of ROS pathways and ROS production at the site 
of injury or disease process. Antioxidant agents acting directly at the mitochondrial site may 
promise higher efficacy than non-specific antioxidant agents. However, clinical trials and 
the development of further appropriate and more effective antioxidant agents are 
warranted. 
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